Cancer Res Treat.  2012 Dec;44(4):262-266.

CD10 Is Again Expressed at a Certain Stage during the Neoplastic Process of Bladder Transitional Cell Carcinomas

• Jang TJ

Abstract

PURPOSE
CD10, a membrane-bound zinc-dependent metallopeptidase, is normally expressed in many tissues. Accordingly, the derangement of CD10 expression may be related to development or progression in a variety of tumors. The aim of this study is to examine any association between CD10 expression and clinicopathological parameters in bladder transitional cell carcinomas (TCCs) and the relationship between expression of E-cadherin and CD10.
MATERIALS AND METHODS
Immunohistochemical staining was performed for CD10 and E-cadherin in tissues of 94 TCCs and 10 non-neoplastic bladder mucosa.
RESULTS
Positive immunoreactivity for CD10 was observed in non-neoplastic urothelium at a proportion of 80% and TCCs were observed at a rate of 23%. A positive rate of CD10 expression was observed in 10% of total cases of a low grade tumor and in 35% of those of a high grade tumor. It was also observed in 15% of pTa tumors, 13% of pT1 tumors, and 48% of pT2 tumors. In addition, CD10 expression showed reciprocal correlation with expression of membranous E-cadherin in tumors.
CONCLUSION
CD10 is again expressed at a certain stage during the neoplastic process of TCCs and could play some roles intheir carcinogenesis.

Keyword

Bladder transitional cell carcinomas; Neprilysin; Cadherins

MeSH Terms

Cadherins
Carcinoma, Transitional Cell
Neprilysin
Urinary Bladder
Urothelium
Cadherins
Neprilysin

Figure

• 

  Fig. 1 (A) CD10 in non-neoplastic urothelium, (B) non-invasive low grade transitional cell carcinoma (TCC), (C) carcinoma in situ and (D) invasive high grade TCC (A-D, ×400), and positive rate of CD10 expression in non-neoplastic urothelium and bladder TCC (E, F). CD10 staining was predominantly cytoplasmic in tumor cells and non-neoplastic urothelium. CD10 expression was significantly higher in normal bladder mucosa, compared with TCC and also showed significant correlation with tumor grade and tumor invasion in TCC.

• 

  Fig. 2 (A) E-cadherin in non-invasive low grade transitional cell carcinoma (TCC) and (B) invasive high grade TCC (A and B, ×400). E-cadherin expression was markedly decreased in invasive high grade TCC.

• 

  Fig. 3 The relationship between expression of CD10 and E-cadherin in transitional cell carcinoma (TCC). CD10 expression showed significant correlation with abnormal expression of E-cadherin in TCC.

Reference

1. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17:463–516. PMID: 11687497.

2. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002; 2:657–672. PMID: 12209155.

3. Orlichenko LS, Radisky DC. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis. 2008; 25:593–600. PMID: 18286378.

4. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol. 1997; 139:1861–1872. PMID: 9412478.

5. Malfroy B, Kuang WJ, Seeburg PH, Mason AJ, Schofield PR. Molecular cloning and amino acid sequence of human enkephalinase (neutral endopeptidase). FEBS Lett. 1988; 229:206–210. PMID: 3162217.

6. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 1989; 3:145–151. PMID: 2521610.

7. Maguer-Satta V, Besancon R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells. 2011; 29:389–396. PMID: 21425402.

8. Bircan S, Candir O, Kapucuoglu N, Serel TA, Ciris M, Karahan N. CD10 expression in urothelial bladder carcinomas: a pilot study. Urol Int. 2006; 77:107–113. PMID: 16888412.

9. Seiler R, von Gunten M, Thalmann GN, Fleischmann A. High CD10 expression predicts favorable outcome in surgically treated lymph node-positive bladder cancer patients. Hum Pathol. 2012; 43:269–275. PMID: 21835428.

10. Bahadir B, Behzatoglu K, Bektas S, Bozkurt ER, Ozdamar SO. CD10 expression in urothelial carcinoma of the bladder. Diagn Pathol. 2009; 4:38. PMID: 19917108.

11. Murali R, Delprado W. CD10 immunohistochemical staining in urothelial neoplasms. Am J Clin Pathol. 2005; 124:371–379. PMID: 16191505.

12. Abdou AG. CD10 expression in tumour and stromal cells of bladder carcinoma: an association with bilharziasis. APMIS. 2007; 115:1206–1218. PMID: 18092952.

13. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998; 22:1435–1448. PMID: 9850170.

14. Koiso K, Akaza H, Ohtani M, Miyanaga N, Aoyagi K. A new tumor marker for bladder cancer. Int J Urol. 1994; 1:33–36. PMID: 7627835.

15. McIntosh GG, Lodge AJ, Watson P, Hall AG, Wood K, Anderson JJ, et al. NCL-CD10-270: a new monoclonal antibody recognizing CD10 in paraffin-embedded tissue. Am J Pathol. 1999; 154:77–82. PMID: 9916921.

16. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol. 2000; 113:374–382. PMID: 10705818.

17. Bai M, Agnantis NJ, Skyrlas A, Tsanou E, Kamina S, Galani V, et al. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. Mod Pathol. 2003; 16:471–480. PMID: 12748254.

18. Erhuma M, Kobel M, Mustafa T, Wulfanger J, Dralle H, Hoang-Vu C, et al. Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues. Int J Cancer. 2007; 120:2393–2400. PMID: 17294442.

19. Ganju RK, Sunday M, Tsarwhas DG, Card A, Shipp MA. CD10/NEP in non-small cell lung carcinomas: relationship to cellular proliferation. J Clin Invest. 1994; 94:1784–1791. PMID: 7962523.

20. Terauchi M, Kajiyama H, Shibata K, Ino K, Mizutani S, Kikkawa F. Anti-progressive effect of neutral endopeptidase 24.11 (NEP/CD10) on cervical carcinoma in vitro and in vivo. Oncology. Oncology. 2005; 69:52–62. PMID: 16103735.

21. Tokuhara T, Adachi M, Hashida H, Ishida H, Taki T, Higashiyama M, et al. Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg. 2001; 49:489–496. PMID: 11552274.

22. Xie L, Moroi Y, Tsuji G, Liu M, Hayashida S, Takahara M, et al. CD10-bearing fibroblast inhibits matrigel invasive potency of interleukin-1alpha-producing squamous cell carcinoma by diminishing substance P levels in the tumor microenvironment. Cancer Sci. 2010; 101:2570–2578. PMID: 20874839.

23. Fujita S, Taniguchi H, Yao T, Shimoda T, Ueno H, Hirai T, et al. Multi-institutional study of risk factors of liver metastasis from colorectal cancer: correlation with CD10 expression. Int J Colorectal Dis. 2010; 25:681–686. PMID: 20204382.

24. Baumgart E, Cohen MS, Silva Neto B, Jacobs MA, Wotkowicz C, Rieger-Christ KM, et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res. 2007; 13:1685–1694. PMID: 17363521.

25. Jang TJ, Cha WH, Lee KS. Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas. Virchows Arch. 2010; 457:319–328. PMID: 20582552.